- Home
- AU vs ITCI Comparison
AU vs ITCI Comparison
Compare AU & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- ITCI
- Stock Information
- Founded
- AU 1944
- ITCI 2002
- Country
- AU United States
- ITCI United States
- Employees
- AU N/A
- ITCI 561
- Industry
- AU Precious Metals
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- AU Basic Materials
- ITCI Health Care
- Exchange
- AU Nasdaq
- ITCI Nasdaq
- Market Cap
- AU 9.6B
- ITCI 8.0B
- IPO Year
- AU 1972
- ITCI N/A
- Fundamental
- Price
- AU $28.78
- ITCI $75.07
- Analyst Decision
- AU Hold
- ITCI Strong Buy
- Analyst Count
- AU 5
- ITCI 11
- Target Price
- AU $28.50
- ITCI $93.55
- AVG Volume (30 Days)
- AU 1.6M
- ITCI 443.1K
- Earning Date
- AU 08-06-2024
- ITCI 10-31-2024
- Dividend Yield
- AU 0.77%
- ITCI N/A
- EPS Growth
- AU N/A
- ITCI N/A
- EPS
- AU 0.27
- ITCI N/A
- Revenue
- AU $4,948,000,000.00
- ITCI $564,526,000.00
- Revenue This Year
- AU $27.08
- ITCI $46.60
- Revenue Next Year
- AU $4.09
- ITCI $37.06
- P/E Ratio
- AU $105.12
- ITCI N/A
- Revenue Growth
- AU 9.18
- ITCI 54.31
- 52 Week Low
- AU $14.91
- ITCI $45.50
- 52 Week High
- AU $32.57
- ITCI $84.89
- Technical
- Relative Strength Index (RSI)
- AU 45.25
- ITCI 50.17
- Support Level
- AU $28.31
- ITCI $71.75
- Resistance Level
- AU $29.40
- ITCI $76.12
- Average True Range (ATR)
- AU 0.64
- ITCI 1.61
- MACD
- AU -0.40
- ITCI -0.06
- Stochastic Oscillator
- AU 11.03
- ITCI 41.16
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.